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Abstract
Purpose Hormone replacement therapy (HRT) use increases breast cancer risk and mammographic density (MD). We 
examine whether MD mediates or modifies the association of HRT with the breast cancer.
Methods For the 4,501 participants in the Danish diet, cancer and health cohort (1993–1997) who attended mammographic 
screening in Copenhagen (1993–2001), MD (mixed/dense or fatty) was assessed at the first screening after cohort entry. 
HRT use was assessed by questionnaire and breast cancer diagnoses until 2012 obtained from the Danish cancer registry. 
The associations of HRT with MD and with breast cancer were analyzed separately using Cox’s regression. Mediation 
analyses were used to estimate proportion [with 95% confidence intervals (CI)] of an association between HRT and breast 
cancer mediated by MD.
Results 2,444 (54.3%) women had mixed/dense breasts, 229 (5.4%) developed breast cancer, and 35.9% were current HRT 
users at enrollment. Compared to never users, current HRT use was statistically significantly associated with having mixed/
dense breasts (relative risk and 95% CI 1.24; 1.14–1.35), and higher risk of breast cancer (hazard ratio 1.87; 1.40–2.48). 
Association between current HRT use and breast cancer risk was partially mediated by MD (percent mediated = 10%; 95% 
CI 4–22%). The current HRT use-related breast cancer risk was higher in women with mixed/dense (1.94; 1.37–3.87) than 
fatty (1.37; 0.80–2.35) breasts (p value for interaction = 0.15).
Conclusions MD partially mediates some of the association between HRT and breast cancer risk. The association between 
HRT and breast cancer seems to be stronger in women with dense breasts.
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Abbreviations
HRT  Hormone replacement therapy
MD  Mammographic density
DCH  Danish diet, cancer and health cohort
OR  Odds ratio
HR  Hazard ratio
CI  Confidence intervals
BMI  Body mass index
CEP  Continuous estrogen + progestin
SEP  Sequential estrogen + progestin
Introduction
Mammographic density (MD) is increasingly being used as 
a biomarker of breast cancer risk, as it is one of the strong-
est risk factors [1]. MD refers to the amount of radiologi-
cally dense breast consisting of epithelial or stromal tissue 
that appears light on a mammogram, whereas fat tissue 
appears dark on a mammogram [2]. Women with very dense 
breasts (> 75% density in the breast) have a four to six times 
greater risk of breast cancer than women with little density 
(< 5–10%) or fatty breasts [1, 2].
Combined estrogen plus progestin hormone replacement 
therapy (HRT) is an established risk factor for breast cancer 
[3–5] although it is still commonly used as an effective treat-
ment for alleviating the climacteric symptoms of menopause 
such as hot flushes, sleeping disturbance, depressive mood, 
muscle, and joint pain. Therefore is it important to evaluate 
whether adverse effects of HRT on breast cancer risk pertain 
to all women, or may be modified by other factors, such as 
MD, so that some women with certain MD (high or low) can 
use HRT while do not react on it [6–8]. Combined estrogen 
plus progestin refers to different treatment regimens includ-
ing cyclical HRT, also known sequential estrogen + proges-
tin (SEP) and continuous estrogen + progestin (CEP) [9]. 
SEP therapy refers to use of estrogen daily with progestin 
added to it for 10–14 days every 4 weeks, while CEP therapy 
refers to continuous use of estrogen and progestin on a daily 
basis [9].
A number of studies have shown that current use of 
HRT increases MD [10–14] and that positive association 
between HRT and MD is of similar magnitude to that of 
HRT and breast cancer [4, 5]. Thus, it was suggested that 
HRT increases risk of breast cancer via its effect on MD, and 
that MD is thus the mediating factor [15–17]. However, this 
is not fully understood, with only three studies to date. Boyd 
et al. found that association between HRT and breast cancer 
was robust to adjustment for MD, concluding that the effects 
of HRT on MD, and on breast cancer risk, respectively, are 
separate and not related causally, but has not conducted 
formal mediation analyses [15]. Rice et al. found that the 
association between current HRT use and breast cancer in 
postmenopausal women was statistically significantly medi-
ated by percent MD, by 22% [16]. Finally, Byrne et al. found 
that increase in breast cancer risk among postmenopausal 
women using estrogen plus progestin HRT regimen was 
completely mediated by increase in MD [17].
Furthermore, it has been suggested that the impact of 
HRT use on breast cancer risk varies by MD. Hou et al. 
found that the HRT use was associated with the highest 
breast cancer risk in women with very dense breasts, while 
no excess risk was found with HRT use in women with fatty 
breasts [7]. Similarly, a case–control study by Boyd et al. 
reported significantly stronger positive associations between 
HRT use and MD in breast cancer cases than in controls [6]. 
Kerlikowske et al. concluded that women with high breast 
density have the added increased risk of breast cancer when 
taking HRT [8]. Furthermore, they had data on HRT regi-
mens and found excess breast cancer risk with both, estrogen 
and estrogen plus progestin [8].Yaghjyan et al. found that 
women with dense breast who are current user of HRT are 
at significant higher risk of breast cancer than previous and 
never user of HRT [18].
The purpose of this study is to determine whether the 
effect of HRT on breast cancer risk is mediated or modified 
by its effect on MD, separately for different HRT regimens: 
estrogen (E), SEP, and CEP.
Patients and methods
Danish diet, cancer and health cohort
Between 1993 and 1997, a total of 160,725 persons (72,729 
women), 50–64 years of age, born in Denmark, living in 
Copenhagen or Aarhus (the two largest cities in Denmark), 
and with no record of cancer in the Danish Cancer Registry, 
were invited to participate in the Danish prospective diet, 
cancer and health (DCH) cohort. In total, 57,053 people, of 
whom 29,875 were women (37% of invited women and 7% 
of the entire Danish female population in this age group), 
accepted the invitation and participated in the study and 
answered a detailed questionnaire on diet, health, educa-
tion, occupation, lifestyle, and reproductive characteristics. 
A detailed description of the DCH cohort has been published 
previously [19].
Study cohort
The study cohort consist of 4,501 postmenopausal women 
from the Danish diet, cancer and health cohort who partici-
pated in the Copenhagen mammography screening program 
between 1991 and 2001.
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HRT exposure assessment
Participants of the DCH cohort reported at the baseline life-
style questionnaire information on use of HRT at enrollment 
(never/previous/current), the age at which they began using 
HRT, the duration (years) of HRT use, and the brand of HRT 
product used. ‘Triers’ were defined as former HRT users 
with less than 6 months of use. Based on the self-reported 
brand of HRT product used, the HRT regimen was coded as 
either unopposed estrogen or as estrogen + progestin com-
bination, which was further classified as either continuously 
administered estrogen + progestin (CEP) or sequentially 
administered estrogen + progestin (SEP).
Confounders and co‑morbidity
The DCH lifestyle questionnaire provided information about 
physical activity in leisure time (yes/no), alcohol use (g/day), 
education (≤ 7, 8–10, > 10 years), parity, number of children, 
age at first birth, history of hysterectomy, and history of 
benign breast tumor. Body mass index (BMI) was measured 
by trained professionals at baseline. Women were divided 
into three birth year intervals (1929–1934, 1935–1939, and 
1940–1946) to account for birth-cohort effects. Women were 
defined as postmenopausal at the cohort baseline if they 
reported having no menstruation within 12 months prior to 
the baseline questionnaire.
MD definition
The Copenhagen mammography screening program started 
in 1991 [20, 21] and targeted about 40,000 women aged 
50–69 years at the start of each biennial invitation round. 
Women were free to refuse to participate in screening as 
well as to decline further invitations. We used data from the 
first screening of 134,640 women who participated in first 
five rounds of screening between 1991 and 2001 [20]. One 
radiologist was in charge of the screening, which occurred 
at a single Copenhagen hospital. At women’s first screening, 
a two-view mammography, craniocaudal and oblique, was 
taken by the radiographers or X-ray nurses. Analog mam-
mography was used, and mammograms were evaluated inde-
pendently by visual assessment by two trained radiologists, 
who did not meet the attending women, unless they were 
recalled for assessment. Attending women were asked to 
fill in a questionnaire about HRT use, earlier breast surgery, 
family history of breast cancer, and eventual suspicion of a 
breast lump; however, this information was not entered in 
the database of the Copenhagen mammography register, and 
was thus not available for this study. Women with a nega-
tive screening test and fatty breasts were scheduled to have 
only an oblique view at the next screen, whereas women 
with a negative screening test and mixed/dense breasts were 
scheduled for two views, in order to improve sensitivity of 
screening, as masking is more likely in women with mixed/
dense breasts. Radiologists have recorded their recommen-
dation for one- (1) or two-view (2) mammography at the 
subsequent screening for each woman, available as a vari-
able from the Copenhagen mammography register, which 
is a proxy of fatty (1) or mixed/dense (2) MD. Fatty (1) MD 
corresponds to equivalent to breast imaging reporting and 
data system (BI-RADS, Atlas, 2003) [22] code 1 (< 25%) 
and part of code 2 (25–50%), while mixed/dense (2) MD 
corresponds to part of BI-RADS code 2 (25–50%), and BI-
RADS codes 3 (51–75%), and 4. To evaluate MD readings, 
two radiologists had to come to an agreement on the MD 
readings. In cases in which readings did not reach consensus, 
the evaluation was sent to a third radiologist. We could not 
estimate inter-reader agreement in this study population, but 
very experienced readers have generally high inter-observer 
agreement in Copenhagen mammography screening pro-
gram, as documented earlier [23].
This internationally unique dichotomous outcome for MD 
has been successfully validated in 120 mammograms which 
have been assigned both dichotomous and BI-RADS den-
sity classification scores, showing a substantial agreement 
with inter-rater variability (weighted kappa statistic) of 0.75 
[21]. Furthermore, the Danish dichotomous MD score has 
been utilized in several earlier studies, showing the expected 
doubling of breast cancer risk in women with mixed/dense 
as compared to those with fatty breasts [23, 24], as well as 
showing strong inverse association with BMI in childhood 
[25], inverse association with active smoking in adult age 
[26], and no association with air pollution [27], all validating 
this measure of MD.
The Copenhagen mammography register contains infor-
mation for all mammograms, including date of screening, 
MD (fatty or mixed/dense), and outcome of screening 
(negative or positive) taken during the screening program 
between 1991 and 2001, for women living in Copenhagen 
municipality aged between 50 and 69 years. For women who 
were part of the Danish diet, cancer, and health cohort and 
participated in mammographic screening in this period, we 
used MD assessed at the first screening after the cohort base-
line (1993–1997). We did this in order to obtain prospective 
design, with HRT assessed at the cohort baseline, and MD 
assessed after baseline questionnaire on HRT. Average time 
between the cohort baseline and screening at which MD 
was obtained was 1.1 year (median 1 year, 25th percentile 
0.5 years, 75th percentile 1.5 years, min 0.03 years, max 
6.8 years).
Breast cancer definition
We linked the records of 4,501 women using the Danish 
personal identification number (CPR) to the Danish cancer 
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registry [28] to extract breast cancer diagnoses, including 
invasive and in situ cancers (ICD-10 codes C50 and D05) 
between screening (1991–2001) and 31 December 2010, 
and to the civil registration system to extract information on 
emigration or death [29].
Statistical methods
We used generalized linear model (glm) for binary data with 
log link function [relative risk (RR) regression for binary 
data] to examine the association between HRT and MD. 
Since the log–glm model did not converge, we instead fitted 
the model using Cox proportional hazard procedure [30] 
with age as underlying time to examine association (esti-
mate RR and 95% CIs) of MD with HRT use at enrollment 
(ever/never and current/previous/triers/never), HRT dura-
tion, time since HRT cessation, and HRT regimens (estro-
gen CEP, SEP) in separate models. Models were fit in two 
steps: a crude model (model 1), adjusted for age (underlying 
time scale) and in a model adjusted for age, birth cohort, 
education, BMI, alcohol use, physical activity, history of 
benign breast tumor, history of hysterectomy, parity, number 
of children, and age at first birth (model 2). The follow-up 
started on the date of cohort entry (1993–1997) and ended at 
the time of death, emigration, of mammographic screening, 
whichever came first. We used Cox proportional hazards 
regression with age as the underlying time, to investigate 
associations of breast cancer risk with HRT use at enroll-
ment (ever/never and current/previous/triers/never), HRT 
duration, time since HRT cessation, and HRT regimens 
(estrogen CEP, SEP), separately, in three steps: a crude 
model, adjusted for age (age adjusted as age is underly-
ing time scale) and BMI (model 1), a model additionally 
adjusted for birth cohort, education, alcohol use, physical 
activity, history of benign breast tumor, history of hyster-
ectomy, parity, number of children, and age at first birth 
(model 2), and a model 2 additionally adjusted for MD 
(model 3). The follow-up started on the date of cohort entry 
(1993–1997) and ended at a date of breast cancer diagnosis, 
death, emigration, or 31 December 2011, whichever came 
first. We have examined the mediation of the association 
between HRT use at cohort baseline and breast cancer risk 
by MD, by using the method for counterfactual-based media-
tion analysis implemented through natural effect models as 
originally proposed by Lange et al. [31], and adapted to Cox 
setting as detailed in Lange et al. [32]. This method uses 
natural effects Cox model to estimate direct and indirect 
effects on HRs scale, as well as mediated proportion with 
95% CIs. The potential effect modification of an association 
between HRT use and breast cancer by MD was evaluated 
by introducing interaction terms into the Cox model, and 
tested by the Wald test. Main logistic and Cox regression 
analyses were performed in Stata 11.2. Mediation analyses 
were performed in medflex package for R statistical pro-
gramme [33].
The study was entirely based on register data and was 
approved by the Danish data inspection agency (2014-41-
3168). Danish law regarding ethical approval of register-
based research does not require informed consent from study 
participants, thus no contact was made with the participating 
women or their relatives and general practitioners.
Results
Table 1 presents the distribution of the baseline characteris-
tics for 4,501 women from DCH cohort. The majority, 2,444 
(54.3%) of women had mixed/dense breasts and 229 (5.1%) 
developed breast cancer during 15 years of follow-up, giv-
ing incidence rate of 3.4 cases per 1,000 person-years. Half 
of the women, 2,318 (51.5%) reported ever using HRT at 
enrollment, while 1,617 (35.9%) were current users at base-
line. Of 2,318 ever users, 389 (8.6%) women reported using 
estrogen, 312 (6.9%) used SEP, and 1,617 (35.9%) used CEP.
Ever users of HRT at enrollment had significantly higher 
risk of having mixed/dense breasts (RR and 95% CI 1.16; 
1.07–1.26) than never users (Table 2). The highest risk 
was observed for current HRT users at enrollment (1.24; 
1.14–1.35), and there was no association in previous users or 
triers. The risk of having mixed/dense breasts was increased 
by 6% (1.06; 1.02–1.10) for each 5-year use of HRT, but was 
reduced by 6% after each 5-year cessation of HRT use (0.94; 
0.88–1.00, per 5 years after cessation). The association with 
MD was limited to estrogen + progestin users, with high-
est RRs observed in SEP users (1.34; 1.20–1.50) followed 
by CEP users (1.21; 1.01–1.44), while no associating was 
observed with estrogen use (1.08; 0.94–1.23).
Having mixed/dense MD was significantly positively 
associated with the breast cancer risk (HR; 95% CI 1.86; 
1.38–2.52) (Table 3). Ever users of HRT had significantly 
higher risk of breast cancer than non-users (1.56; 1.19–2.04), 
with the highest risk observed in current users at enrollment 
(1.87; 1.40–2.48) and none in previous users or triers. Mean 
time between mammographic screening and breast cancer 
diagnosis was 7.7 years. Women who used CEP had the 
highest risk for breast cancer (3.39; 2.20–5.22), followed by 
users of SEP (2.09; 1.48–2.97) as compared to non-users. 
Estrogen use was not associated with breast cancer risk 
(0.99; 0.59–1.65).
After adjustment for MD, the associations between HRT 
use and breast cancer attenuated slightly in ever (1.49; 
1.13–1.95) and current users (1.76; 1.32–2.34), as well as 
for SEP users (1.94; 1.37–2.69) and CEP (3.21; 2.08–4.94) 
(Table 3).
Ever use of HRT showed statistically significant direct 
(1.49; 1.14–1.98) and indirect effect, or effect mediated 
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by MD (1.05; 1.02–1.08), on breast cancer risk, with esti-
mated mediation proportion of 11% (4–30%) (Table 4). 
Similarly, compared to never use, current use of HRT at 
the cohort baseline showed statistically significant direct 
(1.73; 1.31–2.33) and indirect (1.06; 1.03–1.11) effect on 
breast cancer risk, with a proportion mediated by MD of 
10% (4–21%). There was not enough statistical power to 
estimate mediation for different HRT regimens.
The breast cancer risk related to HRT was highest in 
women with mixed/dense breasts, both in ever (HR; 95% 
CI 1.86; 1.21–2.85) and current (1.94; 1.37–3.87) users at 
enrollment, compared to women with fatty breasts (1.24; 
0.77–1.98 and 1.37; 0.80–2.35, in ever and current users), 
although the differences were not statistically significant (p 
value for interaction 0.22 and 0.15, respectively) (Table 5). 
The association with breast cancer seemed to be strongest 
in SEP users with mixed/dense breasts (2.32; 1.56–3.46) 
with no association in SEP users with fatty breast (0.85; 
0.33–2.20), whereas there was no difference in association 
with estrogen or CEP by MD (p value for interaction = 0.05).
Discussion
We found significantly positive associations between HRT 
use and MD, and breast cancer risk, respectively, limited 
to estrogen + progestin HRT regimens. We also found that 
the effect of HRT use on breast cancer risk was in part, by 
around 10%, mediated by MD. Finally, the overall adverse 
effect of HRT on breast cancer was greater in women with 
higher MD.
We found that ever users of postmenopausal HRT had 
16% greater risk of having mixed/dense MD, with the 
highest risk 24% in current HRT users at enrollment, in 
line with other studies [10–13, 15, 24]. In this study, self-
reported HRT use at cohort baseline in 1993–1997 was 
Table 1  Distribution of baseline characteristics for 4,501 women from diet, cancer and health cohort who participated in mammographic screen-
ing in Copenhagen
SD standard deviation, BMI body mass index
N Total
N = 4,501
Mammographic density Breast cancer
Mixed/dense
N = 2,444
Fatty
N = 2,057
Yes
N = 229
No
N = 4,272
Mean follow-up time (years) 15.0 14.9 15.1 8.8 15.3
Mean (SD) age (years) 4,501 57.4 (4.3) 56.6 (4.2) 58.2 (4.3) 57.2 (4.1) 57.4 (4.3)
Born between 1929 and 1934, n (%) 1,380 (30.7) 585 (23.9) 795 (38.6) 61 (26.6) 1,319 (30.9)
Born between 1935 and 1939, n (%) 1,470 (32.7) 803 (32.9) 667 (32.4) 89 (38.9) 1,381 (32.3)
Born between 1940 and 1946, n (%) 1,651 (36.7) 1,056 (43.2) 595 (28.9) 79 (34.5) 1,572 (36.8)
Mean (SD) BMI (kg/m2) 4,501 26.0 (4.6) 24.6 (3.9) 27.5 (5.0) 25.6 (4.4) 26.0 (4.7)
Short education (≤ 7 years), n (%) 1,688 (37.5) 807 (33.0) 881 (42.8) 78 (34.1) 1,610 (37.3)
Medium education (8–10 years), n (%) 2,186 (48.6) 1,223 (50.0) 963 (46.8) 111 (48.5) 2,075 (48.6)
Long education (> 10 years), n (%) 627 (13.9) 414 (17.0) 213 (10.3) 40 (17.5) 587 (13.7)
Alcohol use, n (%) 4,501 4,345 (96.5) 2,365 (96.8) 1,980 (96.3) 223 (97.4) 4,122 (96.5)
Mean (SD) alcohol use in users (g/day) 4,501 13.8 (16.8) 14.8 (16.8) 12.7 (16.9) 16.2 (16.7) 13.7 (16.8)
Nulliparous, n (%) 4,501 678 (15.1) 449 (18.4) 229 (11.1) 44 (19.2) 634 (14.8)
Mean (SD) number of children 3,823 3.0 (1.4) 2.9 (1.4) 3.1 (1.5) 2.8 (1.4) 3.0 (1.4)
Mean (SD) age at first birth (years) 3,818 22.5 (4.1) 22.7 (4.1) 22.3 (4.1) 22.5 (4.2) 22.5 (4.1)
History of benign breast tumor, n (%) 4,501 587 (13.0) 406 (16.6) 181 (8.8) 46 (20.1) 541 (12.7)
Ever used HRT, n (%) 4,501 2,318 (51.5) 1,404 (57.4) 914 (44.4) 145 (63.3) 2,173 (50.9)
Never used HRT, n (%) 2,183 (48.5) 1,040 (42.5) 1,143 (55.6) 84 (36.7) 2,099 (49.1)
Tried (< 6 months use) HRT, n (%) 389 (8.6) 191 (7.8) 198 (9.6) 12 (5.2) 377 (8.8)
Previously used HRT, n (%) 312 (6.9) 145 (5.9) 167 (8.1) 13 (5.7) 299 (7.0)
Currently using HRT, n (%) 1,617 (35.9) 1,068 (43.7) 549 (26.7) 120 (52.4) 1,497 (35.0)
Mean (SD) duration of HRT use in ever users (years) 1,738 8.0 (5.8) 7.8 (5.9) 8.4 (5.7) 7.5 (5.3) 8.1 (5.9)
Never used HRT, n (%) 2,183 (48.5) 1,040 (54.1) 1,143 (72.4) 84 (44.9) 2,099 (63.4)
Estrogen, n (%) 436 (12.5) 277 (14.4) 159 (10.1) 18 (9.6) 418 (12.6)
Sequential estrogen/progesterone, n (%) 654 (18.7) 461 (24.0) 193 (12.2) 56 (29.9) 598 (18.0)
Continuous estrogen/progesterone, n (%) 227 (6.5) 144 (7.5) 83 (5.3) 29 (15.5) 198 (6.0)
Mean (SD) time since cessation in past users (years) 701 8.4 (5.9) 7.8 (6.1) 8.9 (5.7) 7.7 (5.4) 8.4 (5.9)
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Table 2  Association of HRT 
with MD among 4,501 women 
in diet, cancer and health 
cohort who participated in 
mammographic screening in 
Copenhagen
RR relative risk, HRT hormone replacement therapy use at enrollment, OR odds ratio, CI confidence inter-
val
a Adjusted for age (continuous variable), birth cohort (born 1929–1934, born 1935–1939, born 1940–1946), 
education (< 8 years, 8–10 years, > 10 years), alcohol use (g/day), BMI (continuous variable), nulliparity/
parity, number of children (continuous linear variable), age at first birth (continuous), history of benign 
breast tumor (yes/no)
b Adjusted for HRT duration (continuous variable), HRT use (ever/never),  and time since HRT cessation 
(continuous variable)
Mixed/dense Fatty breasts Age adjusted Fully  adjusteda
N = 2,444 N = 2,057 RR (95% CI) RR (95% CI)
HRT use at enrollment
 Never used HRT 1,040 1,143 1.00 1.00
 Ever used HRT 1,404 914 1.21 (1.12–1.32) 1.16 (1.07–1.26)
 Never used HRT 1,040 1,143 1.00 1.00
 Tried (< 6 months) HRT 191 198 0.98 (0.84–1.14) 0.98 (0.84–1.14)
 Previous user of HRT 145 167 0.94 (0.79–1.13) 0.95 (0.80–1.13)
 Current user of HRT 1,068 549 1.33 (1.22–1.45) 1.24 (1.14–1.35)
 Risk per 5 years of HRT use – – 1.08 (1.04–1.12) 1.06 (1.02–1.10)
 Time since cessation per 5 years – – 0.92 (0.86–0.98) 0.94 (0.88–1.00)
HRT  typeb
 Never used HRT 1,040 1,143 1.00 1.00
 Estrogen 277 159 1.19 (1.04–1.36) 1.08 (0.94–1.23)
 Sequential estrogen/progestin 461 193 1.45 (1.30–1.62) 1.34 (1.20–1.50)
 Continuous estrogen/progestin 144 83 1.30 (1.09–1.55) 1.21 (1.01–1.44)
Table 3  Association of MD and HRT with breast cancer among 4,501 women in diet, cancer and health cohort, with and without adjustment for 
MD/HRT
HRT hormone replacement therapy at enrollment, HR hazards ratio, CI confidence interval
a Incidence rate per 10,000 person-years
b Adjusted for age, BMI (continuous variable), birth cohort (born 1929–1934, born 1935–1939, born 1940–1946), education (< 8 years, 8–10 
years, > 10 years), alcohol use (g/day), physical activity (yes/no), nulliparity/parity, number of children (linear variable), age at first birth (lin-
ear), history of benign breast tumor (yes/no)
Breast cancer Person-years IRa Age and BMI adjusted Fully  adjustedb Mutually (MD and 
HRT) and fully 
 adjustedb
N = 299 HR (95% CI) HR (95% CI) HR (95% CI)
Mammographic density
 Fatty MD 70 31,008 22.6 1.00 1.00 1.00
 Mixed/dense MD 159 36,359 43.7 2.07 (1.54–2.79) 1.86 (1.38–2.52) 1.76 (1.30–2.39)
HRT use at enrollment
 Never used HRT 84 32,635 25.7 1.00 1.00 1.00
 Ever used HRT 145 34,732 41.7 1.62 (1.24–2.12) 1.56 (1.19–2.04) 1.49 (1.13–1.95)
 Never used HRT 84 32,635 25.7 1.00 1.00 1.00
 Tried (< 6 months) HRT 12 5,946 20.2 0.78 (0.43–1.44) 0.78 (0.43–1.43) 0.76 (0.42–1.40)
 Previous user of HRT 13 4,545 28.6 1.11 (0.62–2.00) 1.06 (0.59–1.91) 1.05 (0.58–1.89)
 Current user of HRT 120 24,241 49.5 1.93 (1.46–2.54) 1.87 (1.40–2.48) 1.76 (1.32–2.34)
HRT type
 Never used HRT 84 32,635 25.7 1.00 1.00 1.00
 Estrogen 18 6,635 27.1 1.06 (0.64–1.68) 0.99 (0.59–1.65) 0.94 (0.56–1.57)
 Sequential estrogen/progestin 56 9,803 57.1 2.28 (1.62–23.22) 2.09 (1.48–2.97) 1.94 (1.37–2.69)
 Continuous estrogen/progestin 29 3,231 89.8 3.49 (2.29–5.34) 3.39 (2.20–5.22) 3.21 (2.08–4.94)
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linked to MD assessed at screening on average 1 year after 
cohort baseline. We have furthermore found a 6% increase 
in MD per each 5-year use of HRT and a 6% reduction 
in MD after each 5-year cessation of HRT use in agree-
ment with the majority of the studies on changes in MD 
after HRT cessation [34, 35], expect one who failed to 
show a relationship between time since last HRT use and 
MD [11]. Aiello et al., with data on long-term cessation 
over 10 years in 39,296 US women, found the significant 
decrease of MD after 1 year since cessation, and com-
plete reversal of MD to levels before HRT use after 2 years 
[34]. Four studies have examined the effects of short-term 
HRT cessation on MD, all finding typically increased MD 
in women who continued using HRT, and unchanged or 
decreased MD in those who discontinued use after 2–3 
weeks [35, 36], 2 months [37], or 2 years [38]. All these 
results, along with ours, provide strong evidence for the 
dynamic association between HRT use and MD, increasing 
Table 4  Mediation  analysisb of MD and HRT with breast cancer among 4,501 women in diet, cancer and health cohort, with and without adjust-
ment for MD/HRT
HRT hormone replacement therapy at enrollment, HR hazards ratio, CI confidence interval
a Incidence rate per 10,000 person-years
b Adjusted for age, BMI (continuous variable), birth cohort (born 1929–1934, born 1935–1939, born 1940–1946), education (< 8 years, 8–10 
years, > 10 years), alcohol use (g/day), physical activity (yes/no), nulliparity/parity, number of children (linear variable), age at first birth (lin-
ear), history of benign breast tumor (yes/no)
Breast cancer Person-years IRa Total effect Direct effect Indirect effect Percent mediated by MD
N = 299 HR (95% CI) HR (95% CI) HR (95% CI) % (95% CI)
HRT use at enrollment
 Never used HRT 84 32,635 25.7 1.00 1.00 1.00
 Ever used HRT 145 34,732 41.7 1.57 (1.19–2.09) 1.49 (1.14–1.98) 1.05 (1.02–1.08) 11% (4–30%)
 Never used HRT 84 32,635 25.7 1.00 1.00 1.00
 Tried (< 6 months) HRT 12 5,946 20.2 0.79 (0.37–1.35) 0.78 (0.36–1.33) 1.01 (0.99–1.05) − 6% (− 76 to 61%)
 Previous user of HRT 13 4,545 28.6 1.04 (0.50–1.75) 1.03 (0.50–1.73) 1.01 (0.97–1.04) 18% (− 62 to 66%)
 Current user of HRT 120 24,241 49.5 1.85 (1.39–2.49) 1.73 (1.31–2.33) 1.06 (1.03–1.11) 10% (4–22%)
Table 5  Effect modification of association of HRT with breast cancer by MD among 4,501 women in diet, cancer and health cohort who partici-
pated in mammographic screening in Copenhagen
HRT hormone replacement therapy at enrollment, HR hazards ratio, CI confidence interval
a Incidence rate per 10,000 person-years
b Adjusted for birth cohort (born 1929–1934, born 1935–1939, born 1940–1946), education (< 8 years, 8–10 years, > 10 years), alcohol use (g/
day), physical activity (yes/no), BMI (linear variable), nulliparity/parity, number of children (linear variable), age at first birth (linear), history of 
benign breast tumor (yes/no), HRT duration (linear variable), and time since HRT cessation (linear variable)
c p value for interaction
Fatty MD Mixed/dense MD p  valuec
Breast cancer Person-years IRa Fully  adjustedb Breast cancer Person-years IRa Fully  adjustedb
N = 70 31,008 22.6 HR (95% CI) N = 159 36,359 43.7 HR (95% CI)
Never used HRT 36 17,163 21.0 1.00 48 15,471 31.0 1.00
Ever used HRT 34 13,844 24.6 1.24 (0.77–1.98) 111 20,887 53.1 1.86 (1.21–2.85) 0.22
Never used HRT 36 17,163 21.0 1.00 48 15,471 31.0 1.00
Tried (< 6 months) HRT 4 2,999 13.3 0.67 (0.24–1.87) 8 2,947 27.1 0.83 (0.39–1.75)
Previous user of HRT 8 2,412 33.2 1.51 (0.70–3.27) 5 2,133 23.4 0.73 (0.29–1.84)
Current user of HRT 22 8,433 26.1 1.37 (0.80–2.35) 98 15,808 62.0 1.94 (1.37–3.87) 0.15
Never used HRT 36 17,163 21.0 1.00 48 15,471 31.0 1.00
Estrogen 4 2,442 16.4 0.80 (0.28–2.24) 14 4,193 33.4 1.06 (0.58–1.92)
Sequential estrogen/
progestin
5 3,034 16.5 0.85 (0.33–2.20) 51 6,769 75.4 2.32 (1.56–3.46)
Continuous estrogen/
progestin
10 1,209 82.7 2.97 (1.95–8.10) 19 2,021 94.0 3.07 (1.78–5.28) 0.05
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with initiation and prolonged use, and decreasing after 
cessation of use.
Our study suggested there was a significant increase 
in MD with estrogen + progestin HRT regimens, possibly 
stronger for SEP (34%) than CEP (21%), while there was 
no statistically significant association with estrogen use, 
although positive association of 8% was detected. Number of 
the studies found that increase in MD is more pronounced in 
CEP than in SEP and estrogen users [10, 39–42]. Our result 
corroborate those by Greendale et al. who found, in a ran-
domized trial of 307 US women, 7–13 fold increase in MD 
in women using estrogen + progestin regimens as compared 
to unopposed estrogen [39]. Similarly, Marugg et al. has 
found, in 81 Dutch women after 1–2 years, increased MD 
in 31% of estrogen + progestin users, and in 8.7% of unop-
posed estrogen users [10]. Lundstrom et al. has found in 175 
Swedish women over 2 years greater increase in MD in CEP 
(52%) than in SEP (13%) and estrogen (18%) users [40]. 
Topal et al. has in 113 Turkish women, after 14 months, 
detected MD increase in 38.3% of the CEP users, 12.5% of 
cyclic estrogen–progestin users, and only 2.7% of estrogen 
only users [41]. Similarly, Sendag et al. in 216 women, dur-
ing 20 month of follow-up, detected MD increase in 31.1% 
women using continuous combination therapy and only 
in 3.9% of the women using estrogen only [42]. However, 
Erel et al. detected highest (35%) MD increase CEP users 
and 22% increase in estrogen only and 19% in cyclic estro-
gen–progestin users [43], while Aiello et al. found that cur-
rent estrogen–progestin users had a 98%, whereas current 
estrogen users had 71% greater odds of having dense breasts 
[34]. Different HRT regimens may cause different rates of 
MD change, but evidence in which regimens are most rel-
evant for breast density is inconsistent.
We found a strong positive association between estro-
gen–progestin HRT regimen and breast cancer, in agree-
ment with vast evidence [3–5].We detected 87% increase 
in postmenopausal breast cancer associated with current 
HRT use, which is somewhat lower than the RR of 2.22 
(1.80–2.75) reported by Tjonneland et al., who in the same 
cohort, linked HRT use to breast cancer, but with a shorter 
follow-up, until 2000 [4]. Similarly, another Danish study 
by Stahlberg et al. based on Danish Nurse Cohort recruited 
in 1993, found remarkably similar effects of current HRT 
use (2.42; 1.81–3.26) on breast cancer until 2000 [5]. In 
current study with follow-up until 2012, the effect of HRT 
collected at cohort baseline (1993–1997) would be expected 
to be lower compared to estimates from Tjonneland et al. [4]. 
and Stahlberg et al., [5], due to increasing exposure misclas-
sification with increasing time since exposure assessment, 
along with decline in number of HRT users in this period 
[44]. Finally, we found relevance of estrogen + progestin 
regimens, which was most pronounced for CEP and less for 
SEP, in agreement to previous evidence [3–5].
We found that increase in breast cancer risk of 56 and 
87% related to ever and current HRT use, respectively, atten-
uated slightly, by 14 and 13%, respectively, after adjustment 
for MD, by similar magnitude for SEP and CEP (Table 3). 
By performing formal mediation analyses, we found that the 
proportion of association of ever and current HRT use with 
breast cancer mediated by MD was 11 and 10%, respectively 
(Table 4) and statistically significant. This implies that HRT 
use affects breast cancer risk partially via MD, and that this 
proportion was between 4 and 30% for ever-, and 4 and 21% 
for current use. This result is in agreement to that of Boyd 
et al., who in a nested-case–control study from a Canadian 
screening trial, found that an OR for association of current 
HRT use with breast cancer of 1.26 (1.00–1.59) attenu-
ated by 25%–1.19 (0.94–1.51) after adjustment for MD 
[15]. However, Boyd et al. did not perform formal media-
tion analyses and concluded that MD was not a mediator of 
association between HRT and breast cancer, but rather that 
MD and HRT exerted independent effects on breast cancer. 
More recently, Rice et al. however, in agreement with ours, 
reported that MD mediated effect of current HRT use on 
breast cancer risk by 22%, which was statistically significant 
[16]. Finally, the most recent study showed that short-term 
(1-year) effect of estrogen plus progestin daily use, cor-
responding to CEP in our data, on breast cancer risk was 
completely mediated by change in MD [17]. Thus, our study 
corroborates previous evidence that MD acts as mediator of 
an association between HRT and breast cancer, although our 
proportion mediated by MD is lower than that reported in 
other studies. This is possibly explained by our definition of 
MD as binary variable, which is a drastic simplification of a 
finer measure, such as percent MD, used in previous studies. 
This simplification of MD to a binary variable introduced 
measurement error, which in turn biases the indirect effect 
and thus mediated proportion towards null. Hence, the real 
mediated proportion of an association between HRT and 
breast cancer mediated by biological MD is likely higher 
than that presented in this study.
Risk of breast cancer in HRT users differed according to 
MD and was generally higher in women with mixed/dense 
than with fatty MD (Table 5). Ever users of HRT with fatty 
breasts had 24% higher, while those with mixed/dense 
breasts had 86% higher breast cancer risk (p value for inter-
action = 0.22). The difference was even stronger in current 
HRT users, where women with fatty breasts had 37% and 
women with mixed/dense breasts had 94% increased risk of 
breast cancer (p = 0.15). This is in agreement with results 
by Hou et al., which directly assessed the effect modifica-
tion of association between HRT and breast cancer by MD, 
though in American women with different racial composi-
tion from Danish women [7]. Hou et al. found that the HRT 
use was associated with the highest breast cancer risk in 
women with extremely dense breasts (OR range for ever 
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HRT use: 1.22–1.49), with no excess risk in women with 
almost entirely fat breasts [7]. Similarly, a case–control 
study by Boyd et al. which studied the association between 
percent MD (PMD) and breast cancer by HRT use, reported 
6% higher MD in HRT users (compared to never users) who 
were breast cancer cases, and 1.6% in controls using HRT as 
compared to never users (p = 0.001) [6]. Kerlikowske et al. 
concluded that women with high breast density (compar-
ing BI-RADS density 4–2, comparable to our mixed/dense 
category) have the added increased risk of breast cancer 
when taking HRT (2.02; 1.35–1.68), as compared to those 
not taking HRT (1.51; 1.35–1.68) [6]. Furthermore, Ker-
likowske et al. found excess breast cancer risk with both 
estrogen (1.99; 1.61–2.46) and estrogen + progestin (2.09; 
1.79–2.43) use [8], while we detected no association with 
estrogen, positive and similar associations with CEP in both 
groups, and differential associations with SEP by MD, that 
seemed limited to women with dense breasts. Yaghjyan et al. 
found that women with dense breasts (comparing percent 
density > 50% vs. < 10%) who were current users of HRT, 
had significantly higher risk of breast cancer (OR: 5.34; 
95% CI 3.36–8.49) than previous (2.69; 1.32–5.49) or never 
(2.57; 1.18–5.60) HRT user [45].
Several biological mechanisms behind association of 
HRT use and MD have been suggested. Previous studies 
showed the association between serum estradiol level and 
MD changes in women who used HRT, which support pro-
liferative effect of estrogen on breast epithelial cell [46, 47]. 
Similarly, breast epithelial cell proliferations were observed 
in menstruating women due to high levels of estrogen and 
progestin [48]. In line with our findings, it has been shown 
that use of estrogen + progestin combination is associated 
with higher level of breast epithelial cell proliferation than 
in estrogen alone and non-HRT users [46]. Breast epithelial 
cell proliferation is also known as epithelial hyperplasia, 
defined as abnormal growth and accumulation of cells that 
line the ducts or the lobules in the breasts, which may lead 
to increased breast cancer risk [49]. Therefore, higher levels 
of epithelial hyperplasia associated with estrogen + proges-
tin combination use likely explain increased MD and breast 
cancer risk with this HRT regimen, as compared to estrogen 
alone and no HRT use [50, 51]. Thus it is plausible that some 
of the increased risk of breast cancer related to HRT use 
is mediated via increase in MD by HRT use, likely estro-
gen +  progestin use, as suggested by our results. In addi-
tion, a recent study suggests that high MD is associated with 
a more aggressive breast cancer tumors type, especially in 
women taking estrogen + progesterone HRT regimen [45].
This study benefited from an ability, unique to Denmark, 
to link breast density data from Copenhagen mammogra-
phy register to a large prospective Danish DCH cohort, with 
detailed information on HRT and breast cancer risk factors, 
and facilitate the data to study whether MD mediates the 
effect of HRT on breast cancer risk, explored in few other 
studies to date [15–17]. DCH data on HRT use and breast 
cancer risk factors were collected independently of and 
before mammography screening, limiting the possibility of 
recall or information bias. HRT data have been validated 
and utilized before in an earlier study in this cohort link-
ing HRT to breast cancer [4]. However, a limitation of this 
study is that we have assessed HRT use only at the enroll-
ment in 1993–1997, and thus we cannot account for change 
in HRT use status during the follow-up, and corresponding 
exposure misclassification is likely to bias effect estimates 
towards zero. We utilized a Danish dichotomized MD score 
as mixed/dense or fatty breasts, as no other measure of MD 
was available, in contrast to a variety of measures of MD 
used in related studies, including BI-RADS or percent MD. 
However, this dichotomous outcome has been utilized in 
earlier studies of MD and breast cancer mortality [23], early 
childhood BMI and MD [25], active tobacco smoking and 
MD [26], alcohol use and MD [52], and air pollution and 
MD [27], and showed an expected doubling of the breast 
cancer risk in women with mixed/dense compared to women 
with fatty breasts, in agreement with Boyd et al. [1] Fur-
thermore, we have successfully validated dichotomous MD 
measure and found good agreement with BI-RADS [23]. 
A weakness of the study is the small sample size for HRT 
regimens, as well as lack of data on history of breast cancer, 
which is an important determinant of MD as well as breast 
cancer risk. Finally, the major weakness of the study is the 
lack of data on MD change during follow-up, which would 
facilitate the optimal design to study whether MD mediates 
the association between HRT use and breast cancer risk, 
but this was however not possible neither in the other stud-
ies on the topic [15, 16]. Thus, we cannot exclude the pos-
sibility that the larger effect of HRT on breast cancer in the 
mixed/dense group may be due to the fact that these are the 
women who experienced a higher MD in response to HRT, 
and other studies need to address this. Considering the lack 
of data on MD change, and utilization of crude measure of 
MD, both of which would likely bias our results towards 
zero, our findings of 10–11% of the association of HRT and 
breast cancer being explained by MD are likely underesti-
mated. This confirms that, despite limitations in our design, 
we contribute with novel evidence that MD is a likely on a 
biological pathway from HRT use to increased breast cancer 
risk, but also that other mechanisms are at play.
Conclusion
We found significantly positive associations between HRT 
use and MD, as well as between HRT and breast cancer 
risk, which seemed limited to estrogen + progestin HRT 
regimens. We found that the association between HRT use 
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and breast cancer risk was in part, by around 10%, medi-
ated by MD. This suggests that MD is a mediator of certain 
biological pathways on HRT-related breast cancer develop-
ment, and also that other mechanisms are at play. Finally, 
the association between HRT and breast cancer risk seemed 
more pronounced in women with dense breasts.
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